Search

Your search keyword '"de Acosta, MB"' showing total 5 results
Start Over Author "de Acosta, MB"
5 results on '"de Acosta, MB"'

1. Safety of Inflammatory Bowel Disease treatments in patients with Solid Organ Transplantation (EITOS study of GETECCU)

Author

Rey, IB, Suarez, CC, Luque, AM, Caballol, B, Soutullo, C, Bravo, A, Castano, A, Gros, B, Hurtado, A, Rey, TV, Galan, HA, Canete, F, Castro, B, Galindo, PP, Munoza, CG, El Hajra, I, Montiel, PM, Abreu, IA, Mesonero, F, Vivo, MG, Peries, L, Arranz, EM, Abril, C, Jimenez, IM, Baltar, R, Vicuna, M, Moreno, N, Brunet, E, Lago, IR, de Celix, CR, Fajardo, I, Cruz, N, Feria, MR, Clotet, AF, Gimeno, M, Zabana, Y, Ferrer, CS, and de Acosta, MB

Published
2022

2. Effectiveness and safety of ustekinumab in elderly patients: Real world evidence from ENEIDA registry

Author

Deza, DC, Calvo, LJL, Mainar, JMA, Ricart, E, Gisbert, JP, Tirado, MR, Rodriguez, ES, Sicilia, B, Casbas, AG, Ochoa, OM, Marquez, L, de la Torre, VL, Arranz, MDM, Serrano, PL, Menendez, SR, Munoza, CG, Parga, LD, Moya, MC, Alonso, JG, Esteve, M, Colomino, MI, Gil, MD, de Acosta, MB, Poyatos, RL, Mancenido, N, Caballo, B, Calafat, M, Lago, IR, Capo, JG, Alvarado, VJM, Tardillo, C, Bujanda, L, Nunez, JFM, Nieto, YB, Bermejo, F, Chaparro, M, Almela, P, Navarro, M, Domenech, E, and Lopez, SG

Published
2021

3. Exploring the Relationship Between Self-Isolation and Distress Among People with Gastrointestinal Disorders During the COVID-19 Pandemic

Author

Mikocka-Walus, Antonina, Skvarc, David, de Acosta, MB, Evertsz, FB, Bernstein, CN, Burisch, J, Ferreira, N, Gearry, RB, Graff, LA, Jedel, S, Mokrowiecka, A, Stengel, A, Trindade, IA, van Tilburg, MAL, Knowles, SR, Mikocka-Walus, Antonina, Skvarc, David, de Acosta, MB, Evertsz, FB, Bernstein, CN, Burisch, J, Ferreira, N, Gearry, RB, Graff, LA, Jedel, S, Mokrowiecka, A, Stengel, A, Trindade, IA, van Tilburg, MAL, and Knowles, SR

Published
2021

4. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry

Author

Chaparro M, Garre A, Ricart E, Iborra M, Mesonero F, Vera I, Riestra S, García-Sánchez V, Luisa De Castro M, Martin-Cardona A, Aldeguer X, Mínguez M, de-Acosta MB, Rivero M, Muñoz F, Andreu M, Bargalló A, González-Muñoza C, Pérez Calle JL, García-Sepulcre MF, Bermejo F, Huguet JM, Cabriada JL, Gutiérrez A, Mañosa M, Villoria A, Carbajo AY, Lorente R, García-López S, Piqueras M, Hinojosa E, Arajol C, Sicilia B, Conesa AM, Sainz E, Almela P, Llaó J, Roncero O, Camo P, Taxonera C, Domselaar MV, Pajares R, Legido J, Madrigal R, Lucendo AJ, Alcaín G, Doménech E, Gisbert JP, and GETECCU study group

Subjects
Adult, Male, medicine.medical_specialty, Antibodies, Monoclonal, Humanized, Communicable Diseases, Inflammatory bowel disease, Vedolizumab, 03 medical and health sciences, 0302 clinical medicine, Crohn Disease, Gastrointestinal Agents, Interquartile range, Internal medicine, medicine, Humans, Pharmacology (medical), Prospective Studies, Registries, Adverse effect, Prospective cohort study, Hepatology, business.industry, Proportional hazards model, Remission Induction, Gastroenterology, Middle Aged, Inflammatory Bowel Diseases, medicine.disease, Ulcerative colitis, Discontinuation, Treatment Outcome, Spain, 030220 oncology & carcinogenesis, Colitis, Ulcerative, Female, 030211 gastroenterology & hepatology, business, Follow-Up Studies, medicine.drug
Abstract

Background: Effectiveness of vedolizumab in real world clinical practice is unknown. Aim: To evaluate the short and long-term effectiveness of vedolizumab in patients with inflammatory bowel disease (IBD). Methods: Patients who received at least 1 induction dose of vedolizumab were included. Effectiveness was defined based on Harvey-Bradshaw index (HBI) in Crohn's disease (CD) and Partial Mayo Score (PMS) in ulcerative colitis (UC). Short-term response was assessed at week 14. Variables associated with short-term remission were identified by logistic regression analysis. The Kaplan-Meier method was used to evaluate the long-term durability of vedolizumab treatment. Cox model was used to identify factors associated with discontinuation of treatment and loss of response. Results: 521 patients were included (median follow-up 10 months [interquartile range 5-18 months]). At week 14, 46.8% had remission and 15.7% clinical response. CD (vs UC), previous surgery, higher CRP concentration and disease severity at baseline were significantly associated with impaired response. The rate of vedolizumab discontinuation was 37% per patient-year of follow-up (27.6% in UC and 45.3% in CD, P < 0.01). CD (vs UC), anaemia at baseline, steroids during induction and CRP concentration were associated with lower durability of treatment. Seven per cent of patients developed adverse events, infections being the most frequent. Conclusions: Over 60% of IBD patients respond to vedolizumab. Many patients discontinue treatment over time. CD and disease burden impair both short- and long-term response. Vedolizumab seems to be safe in clinical practice.

Published
2018
Full Text
View/download PDF

5. Exploring the Relationship Between Self-Isolation and Distress Among People with Gastrointestinal Disorders During the COVID-19 Pandemic.

Author

Mikocka-Walus A, Skvarc D, de Acosta MB, Evertsz FB, Bernstein CN, Burisch J, Ferreira N, Gearry RB, Graff LA, Jedel S, Mokrowiecka A, Stengel A, Trindade IA, van Tilburg MAL, and Knowles SR

Subjects
Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Pandemics, SARS-CoV-2, COVID-19, Gastrointestinal Diseases epidemiology
Abstract

This study aimed to explore the association between perceived isolation and symptoms of distress in people with GI disorders at the time of the pandemic; and to examine factors which moderate this relationship. This online cross-sectional survey was advertised in May-September 2020 via patient organisations and associated social media. Overall, 831 people (82% female, mean age 49 years) from 27 countries participated. A significant relationship between social isolation and psychological distress was noted (r = .525, p < .001). GI symptoms moderated the association between isolation and distress (B = .047, t = 2.47, p = .015). Interventions targeting these factors may help to reduce distress in people with GI disorders at the time of major stressors such as the COVID-19 pandemic., (© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results